ATE397669T1 - Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse- transkriptase - Google Patents
Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse- transkriptaseInfo
- Publication number
- ATE397669T1 ATE397669T1 AT03761600T AT03761600T ATE397669T1 AT E397669 T1 ATE397669 T1 AT E397669T1 AT 03761600 T AT03761600 T AT 03761600T AT 03761600 T AT03761600 T AT 03761600T AT E397669 T1 ATE397669 T1 AT E397669T1
- Authority
- AT
- Austria
- Prior art keywords
- drug
- hiv
- drug resistance
- phenotypical
- reverse transcriptase
- Prior art date
Links
- 206010059866 Drug resistance Diseases 0.000 title abstract 2
- 101900297506 Human immunodeficiency virus type 1 group M subtype B Reverse transcriptase/ribonuclease H Proteins 0.000 title 1
- 230000002596 correlated effect Effects 0.000 title 1
- 230000035772 mutation Effects 0.000 title 1
- 230000000869 mutational effect Effects 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 1
- 238000004458 analytical method Methods 0.000 abstract 1
- 238000012512 characterization method Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000009510 drug design Methods 0.000 abstract 1
- 238000009509 drug development Methods 0.000 abstract 1
- 238000007876 drug discovery Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/702—Specific hybridization probes for retroviruses
- C12Q1/703—Viruses associated with AIDS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
- G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
- G01N2333/16—HIV-1, HIV-2
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/91245—Nucleotidyltransferases (2.7.7)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/91245—Nucleotidyltransferases (2.7.7)
- G01N2333/9125—Nucleotidyltransferases (2.7.7) with a definite EC number (2.7.7.-)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
- Biomedical Technology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39300502P | 2002-07-01 | 2002-07-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE397669T1 true ATE397669T1 (de) | 2008-06-15 |
Family
ID=30000959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03761600T ATE397669T1 (de) | 2002-07-01 | 2003-06-30 | Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse- transkriptase |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7473524B2 (de) |
| EP (1) | EP1522039B1 (de) |
| AT (1) | ATE397669T1 (de) |
| AU (1) | AU2003251732B2 (de) |
| CA (1) | CA2490764C (de) |
| DE (1) | DE60321466D1 (de) |
| WO (1) | WO2004003223A2 (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1185712B8 (de) * | 1999-05-28 | 2005-10-19 | Virco Bvba | Neue mutationsprofile der hiv-1 reverse transcriptase in verbindung mit phänotypischem medikamentresistenz |
| MXPA03003476A (es) * | 2000-10-20 | 2004-09-10 | Virco Bvba | Nuevos perfiles mutacionales en transcriptasa inversa de vih-1 correlacionan con resistencia fenotipica a farmaco. |
| WO2004003223A2 (en) * | 2002-07-01 | 2004-01-08 | Tibotec Pharmaceuticals Ltd. | New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance |
| EP1520247B1 (de) * | 2002-07-01 | 2009-05-27 | Tibotec Pharmaceuticals Ltd. | Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-protease |
| US20050214744A1 (en) * | 2002-07-01 | 2005-09-29 | Hilde Azjin | New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance |
| WO2008124192A2 (en) * | 2007-04-10 | 2008-10-16 | Emory University | Novel hiv-1 reverse transcriptase codon deletion and its use in the management and treatment of hiv infections |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US327742A (en) | 1885-10-06 | Machine for making nuts | ||
| DE3235565A1 (de) | 1982-09-25 | 1984-03-29 | Boehringer Ingelheim KG, 6507 Ingelheim | Piperidinderivate, ihre herstellung und verwendung |
| JPS5974341A (ja) | 1982-10-19 | 1984-04-26 | Nissan Motor Co Ltd | 車両用アクセル制御装置 |
| GB2229340B (en) | 1989-03-17 | 1994-02-09 | Technophone Ltd | Radio telephone system |
| GB8918226D0 (en) | 1989-08-09 | 1989-09-20 | Wellcome Found | Dna assays |
| EP0428000A1 (de) | 1989-11-03 | 1991-05-22 | Abbott Laboratories | Fluorogene Substrate zum Nachweis von proteolytischer Enzymaktivität |
| US5235039A (en) | 1991-06-10 | 1993-08-10 | Eli Lilly And Company | Substrates for hiv protease |
| WO1993023574A1 (en) | 1992-05-14 | 1993-11-25 | Kozal Michael J | Polymerase chain reaction assays for monitoring antiviral therapy |
| US6063562A (en) | 1994-09-16 | 2000-05-16 | Sepracor, Inc. | In vitro method for predicting the evolutionary response of HIV protease to a drug targeted thereagainst |
| US6087093A (en) | 1996-01-26 | 2000-07-11 | Innogenetics N.V. | Method for detection of drug-induced mutations in the reverse transcriptase gene |
| AU717755B2 (en) | 1996-01-26 | 2000-03-30 | Virco Bvba | Method of managing the chemotherapy of patients who are HIV positive based on the phenotypic drug sensitivity of human HIV strains |
| CN1263867C (zh) | 1996-01-29 | 2006-07-12 | 病毒科学公司 | 用于确定抗病毒药物敏感性和抗性和筛选抗病毒药物的组合物和方法 |
| JP3062459B2 (ja) | 1996-08-14 | 2000-07-10 | 理化学研究所 | ポリエステル重合酵素遺伝子及びポリエステルの製造方法 |
| CA2329140A1 (en) | 1998-05-26 | 1999-12-02 | Virologic, Inc. | Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy |
| AU4673399A (en) | 1998-05-28 | 1999-12-13 | Visible Genetics Inc. | Use of polymorphisms as a predictor of drug-resistance mutations |
| AU771780B2 (en) | 1998-06-23 | 2004-04-01 | Board Of Trustees Of The University Of Illinois, The | Fitness assay and associated methods |
| WO1999067428A2 (en) | 1998-06-24 | 1999-12-29 | Innogenetics N.V. | Method for detection of drug-selected mutations in the hiv protease gene |
| MXPA00012843A (es) | 1998-06-24 | 2002-04-24 | Virologic Inc | Medios y metodo para verificar la terapia antirretroviral con un inhibidor nucleosico de la transcriptasa inversa y guia de decisiones terapeuticas en el tratamiento del vih/sida. |
| EP1185712B8 (de) * | 1999-05-28 | 2005-10-19 | Virco Bvba | Neue mutationsprofile der hiv-1 reverse transcriptase in verbindung mit phänotypischem medikamentresistenz |
| EP1194587A4 (de) * | 1999-06-22 | 2005-07-06 | Virologic Inc | Mittel und verfahren zum überwachen von antiretroviralen therapien mit proteaseinhibitorenund entscheidungshilfe bei therapien in der behandlung von hiv/aids |
| WO2000078994A1 (en) | 1999-06-23 | 2000-12-28 | The Penn State Research Foundation | Compositions and methods for the quantification of sterol biosynthetic flux |
| AU2001260224A1 (en) | 2000-04-18 | 2001-10-30 | Virco Bvba | Methods for measuring drug resistance |
| AU2001256318B8 (en) | 2000-04-20 | 2007-03-22 | Virco Bvba | Method for mutation detection in HIV using pol sequencing |
| US7058616B1 (en) | 2000-06-08 | 2006-06-06 | Virco Bvba | Method and system for predicting resistance of a disease to a therapeutic agent using a neural network |
| EP1352356B1 (de) | 2000-06-08 | 2009-10-14 | Virco Bvba | Verfahren um die resistenz gegen ein therapeutisches agenz vorherzusagen unter verwendung neuronaler netze |
| WO2002022076A2 (en) | 2000-09-15 | 2002-03-21 | Virologic, Inc. | Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids |
| EP1340075B1 (de) | 2000-10-20 | 2009-01-28 | Virco Bvba | Festlegen von kritischen biologischen werten zur voraussage einer therapieresistenz |
| MXPA03003476A (es) | 2000-10-20 | 2004-09-10 | Virco Bvba | Nuevos perfiles mutacionales en transcriptasa inversa de vih-1 correlacionan con resistencia fenotipica a farmaco. |
| JP2002199890A (ja) | 2000-10-23 | 2002-07-16 | Inst Of Physical & Chemical Res | 生分解性ポリエステル合成酵素の改変方法 |
| EP1364071A2 (de) | 2000-11-10 | 2003-11-26 | Bioalliance Pharma (S.A.) | Neue methode zur analyse von phänotypischen eigenschaften des humanen immunschwächevirus (hiv) |
| ES2275866T3 (es) | 2001-02-14 | 2007-06-16 | Tibotec Pharmaceuticals Ltd. | 2-(aminosustituido)-benzotiazol-sulfonamidas de amplio esprecto inhibidoras de la proteasa de vih. |
| EP1319738A1 (de) | 2001-12-17 | 2003-06-18 | Atofina Research S.A. | Modifizierte Polyolefinfasern |
| EP1520247B1 (de) | 2002-07-01 | 2009-05-27 | Tibotec Pharmaceuticals Ltd. | Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-protease |
| WO2004003223A2 (en) | 2002-07-01 | 2004-01-08 | Tibotec Pharmaceuticals Ltd. | New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance |
| US7294642B2 (en) | 2002-09-06 | 2007-11-13 | Elan Pharmaceuticals, Inc. | 1,3-Diamino-2-hydroxypropane pro-drug derivatives |
| EP1605064A1 (de) | 2004-06-07 | 2005-12-14 | UMC Utrecht Holding B.V. | HIV Varianten, welche einen neuen Resistenzmechanismus gegenüber Proteaseinhibitoren zeigen, diagnostische Assays zum Nachweis der Varianten, und Methoden zur Identifikation von Medikamenten, welche gegen die resistenten Varianten wirksam sind. |
-
2003
- 2003-06-30 WO PCT/EP2003/050280 patent/WO2004003223A2/en active IP Right Grant
- 2003-06-30 DE DE60321466T patent/DE60321466D1/de not_active Expired - Lifetime
- 2003-06-30 US US10/518,525 patent/US7473524B2/en not_active Expired - Fee Related
- 2003-06-30 CA CA2490764A patent/CA2490764C/en not_active Expired - Fee Related
- 2003-06-30 AU AU2003251732A patent/AU2003251732B2/en not_active Ceased
- 2003-06-30 EP EP03761600A patent/EP1522039B1/de not_active Expired - Lifetime
- 2003-06-30 AT AT03761600T patent/ATE397669T1/de active
-
2008
- 2008-10-30 US US12/261,475 patent/US8076062B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2490764A1 (en) | 2004-01-08 |
| EP1522039B1 (de) | 2008-06-04 |
| US20090061420A1 (en) | 2009-03-05 |
| CA2490764C (en) | 2011-11-22 |
| WO2004003223A3 (en) | 2005-02-17 |
| AU2003251732B2 (en) | 2008-09-18 |
| EP1522039A2 (de) | 2005-04-13 |
| DE60321466D1 (de) | 2008-07-17 |
| US7473524B2 (en) | 2009-01-06 |
| US8076062B2 (en) | 2011-12-13 |
| AU2003251732A1 (en) | 2004-01-19 |
| US20050239053A1 (en) | 2005-10-27 |
| WO2004003223A2 (en) | 2004-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Metsky et al. | Capturing sequence diversity in metagenomes with comprehensive and scalable probe design | |
| BR0011555A (pt) | Perfis mutacionais em transcriptase reversa de hiv-1 correlacionada com resistência fenotìpica à droga | |
| Lin et al. | Using amplicon deep sequencing to detect genetic signatures of Plasmodium vivax relapse | |
| Knyazev et al. | Epidemiological data analysis of viral quasispecies in the next-generation sequencing era | |
| Murray et al. | Molecular epidemiology of tuberculosis: achievements and challenges to current knowledge | |
| ATE432506T1 (de) | Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-protease | |
| ATE217105T1 (de) | Verfahren und vorrichtung zur unterstützung eines benutzers zum erzeugen eines medizinischen protokolls | |
| Mukherjee et al. | Switching between raltegravir resistance pathways analyzed by deep sequencing | |
| ATE397669T1 (de) | Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse- transkriptase | |
| Otter et al. | Identifying patient‐reported outcomes in rheumatoid arthritis: the impact of foot symptoms on self‐perceived quality of life | |
| Van Egeren et al. | Risk of evolutionary escape from neutralizing antibodies targeting SARS-CoV-2 spike protein | |
| ES2609479T3 (es) | Procedimiento implementado por ordenador y sistema informático para la identificación de organismos | |
| WO2004043232A3 (en) | Methods for identifying risk of melanoma and treatments thereof | |
| Tinetti et al. | Modifiable impairments predict progressive disability among older persons | |
| Popa et al. | Mutational dynamics and transmission properties of SARS-CoV-2 superspreading events in Austria | |
| MXPA03003476A (es) | Nuevos perfiles mutacionales en transcriptasa inversa de vih-1 correlacionan con resistencia fenotipica a farmaco. | |
| ATE375400T1 (de) | Neue mutationsmuster in hiv-1 reverser transcriptase, die mit phenotypischer resistenz gegen medikamente korrelieren | |
| Prescott et al. | From linkage maps to quantitative trait loci: the history and science of the Utah genetic reference project | |
| Metsky et al. | Capturing diverse microbial sequence with comprehensive and scalable probe design | |
| Zhao et al. | Phylogenetic estimation of the viral fitness landscape of HIV-1 set-point viral load | |
| Lasek-Nesselquist et al. | A statewide analysis of SARS-CoV-2 transmission in New York | |
| WO2015068089A1 (en) | Hcv genotyping algorithm | |
| D’Addiego et al. | Recovery of complete genome sequences of Crimean-Congo haemorrhagic fever virus (CCHFV) directly from clinical samples: A comparative study between targeted enrichment and metagenomic approaches | |
| Mertz | Finding New Ways to Analyze the Microbiome | |
| Guessous et al. | Trends in pharmacogenomic epidemiology: 2001–2007 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1522039 Country of ref document: EP |